223. 一次性膜性増殖性糸球体腎炎
［臨床試験数：18，薬物数：14（DrugBank：7），標的遺伝子数：7，標的パスウェイ数：14］
Searched query = "Primary membranoproliferative glomerulonephritis", "Dense deposit disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02682407 (ClinicalTrials.gov) | February 2016 | 10/2/2016 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease | IgAN;Lupus Nephritis;MN;C3 Glomerulopathy | Biological: OMS721 (narsoplimab) | Omeros Corporation | NULL | Recruiting | 18 Years | N/A | All | 54 | Phase 2 | United States;Hong Kong |